Hence, we sought to leverage IRS distributions across tumor types (and pan-cancer biomarkers) in the entire SCMD to understand the potential impact of IRS both within and outside of currently approved PD-(L)1 monotherapy indications. The gene discussed is CD274; the disease is cancer.